title: Mouse models of systemic lupus erythematosus reveal a complex pathogenesis.
abstract: The mammalian immune system is remarkable in that it can respond to an essentially infinite number of foreign antigens. The ability to mount a long-lasting (adaptive) immune response against foreign antigen requires the participation of cells selected from an enormously diverse population of B and T cells. Because the B and T cell receptors expressed by these cells are generated at random, a significant percentage of B and T cells are invariably directed against self-antigen. Under normal circumstances, autoreactive B and T cells are eliminated, reprogrammed, or inactivated in the primary and secondary lymphoid organs. Despite these checks and balances, a small but significant number of people and animals still develop autoimmune disease. One such autoimmune disease-systemic lupus erythematosus-is characterized by the loss of B- and T-cell tolerance to self-antigens (principally nuclear), culminating in multisystemic inflammation. Multiple genetic defects, drug exposure, infectious agents, and environmental factors can contribute to the pathogenesis of the disease. Loss of B- and T-cell tolerance precipitates activation of plasmacytoid and myeloid dendritic cells; collectively, these cells cooperate to form a complex positive feedback loop, continually stimulated by the persistence of self-antigen. Novel treatment strategies now focus on specific inhibition of various aspects of the feedback loop. These specific inhibitors have the potential to be more effective and lack the side effects associated with generalized immunosuppression.
authors.affiliation: DVM, PhD, Diplomate ACVP, Pathologist Director, Amgen Inc, 360 Binney Street, Cambridge, MA 02142, USA. jrottman@amgen.com
authors.forename: J B
authors.initials: JB
authors.lastname: Rottman
authors.forename: C R
authors.initials: CR
authors.lastname: Willis
mesh_terms: D056704:Adaptive Immunity / Q000276:immunology*; D000818:Animals; D017209:Apoptosis / Q000276:immunology; D001324:Autoantigens / Q000276:immunology*; D053264:B-Cell Activating Factor / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology*; D004195:Disease Models, Animal; D007108:Immune Tolerance / Q000276:immunology*; D007167:Immunotherapy / Q000379:methods; D016898:Interferon-alpha / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000276:immunology* / Q000628:therapy; D051379:Mice; D008813:Mice, Inbred ICR; D008814:Mice, Inbred NZB; D013601:T-Lymphocytes / Q000276:immunology*; D051193:Toll-Like Receptors / Q000276:immunology
chemical_list: D001324:Autoantigens; D053264:B-Cell Activating Factor; D016898:Interferon-alpha; C505720:Tnfsf13b protein, mouse; D051193:Toll-Like Receptors